Literature DB >> 9886393

Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts.

L S Klavinskis1, C Barnfield, L Gao, S Parker.   

Abstract

The development of vaccines against pathogens transmitted across the genito-rectal mucosa that effectively stimulate both secretory IgA Abs and cytotoxic T lymphocytes in the genital tract and CTL in the draining lymph nodes (LN) has proven a major challenge. Here we report a novel, noninvasive approach of genetic vaccination via the intranasal route. Such vaccination elicits immune responses in the genital and rectal mucosa, draining LNs, and central lymphoid system. Intranasal immunization with plasmid DNA-lipid complexes encoding the model Ag firefly luciferase resulted in dissemination of the DNA and the encoded transcript throughout the respiratory and gastrointestinal tracts, draining LNs, and spleen. Complexing the plasmid DNA with the lipid DMRIE/DOPE enhanced expression of the encoded protein in the respiratory tract, increased specific secretory IgA Ab in the vaginal and rectal tracts, and increased the circulating levels of specific IgA and IgG. In addition, intranasal DNA immunization resulted in generation of Ag-specific CTL that were localized in the genital and cervical LNs and spleen. These results suggest that intranasal immunization with plasmid DNA-lipid complexes may represent a generic immunization strategy against pathogens transmitted across the genito-rectal and other mucosal surfaces.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886393

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice.

Authors:  S Kawabata; Y Terao; T Fujiwara; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 2.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 4.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

5.  Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines.

Authors:  Petra Riedl; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Mol Med (Berl)       Date:  2003-12-02       Impact factor: 4.599

Review 6.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

7.  Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization.

Authors:  Maytal Bivas-Benita; Liat Bar; Geoffrey O Gillard; David R Kaufman; Nathaniel L Simmons; Avi-Hai Hovav; Norman L Letvin
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

8.  CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.

Authors:  Janina Q Jiang; Amy Patrick; Ronald B Moss; Kenneth L Rosenthal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

9.  Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.

Authors:  L M Hodge; M Marinaro; H P Jones; J R McGhee; H Kiyono; J W Simecka
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 10.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.